subscribeSubscribe
KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity

KRAZATI with Cetuximab Demonstrates Clinically Meaningful Activity
BUSINESSWIRE
08 Apr 2024
Share Share
Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint

Zai Lab Partner BMS Announces Trial KRAZATI (adagrasib) Meets Primary Endpoint
BUSINESSWIRE
01 Apr 2024
Share Share
BMS touts KRAS confirmatory trial win after Amgen`s stumble

BMS touts KRAS confirmatory trial win after Amgen`s stumble
Angus Liu FIERCE PHARMA
30 Mar 2024
Share Share
BMS Announces Trial Evaluating KRAZATI Meets Primary Endpoint

BMS Announces Trial Evaluating KRAZATI Meets Primary Endpoint
BUSINESSWIRE
28 Mar 2024
Share Share
FDA Accepts sNDA for KRAZATI in Combination with Cetuximab

FDA Accepts sNDA for KRAZATI in Combination with Cetuximab
BUSINESSWIRE
20 Feb 2024
Share Share
EU body endorses Mirati`s KRAS drug for lung cancer after second look

EU body endorses Mirati`s KRAS drug for lung cancer after second look
PR NEWSWIRE
11 Nov 2023
Share Share
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration

Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration
GLOBENEWSWIRE
02 Nov 2023
Share Share
Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC

Bazhenova Details Potential Pathways Forward for Targeting KRAS in NSCLC
ONCLIVE
28 Aug 2023
Share Share
Mirati`s lung cancer drug fails to win EU regulator`s backing

Mirati`s lung cancer drug fails to win EU regulator`s backing
PRESS RELEASE
22 Jul 2023
Share Share
Mirati`s KRAS drug Krazati beat estimates in first full quarter

Mirati`s KRAS drug Krazati beat estimates in first full quarter
Angus Liu FIERCE PHARMA
11 May 2023
Share Share